July 1, 1973CancerOpen Access

Phase II evaluation of adriamycin in human neoplasia

View Full Paper

Ask AI

Bookmark

Why the study?

Does adriamycin induce objective remissions and what is its toxicity profile in patients with disseminated neoplasia?

Population

472 patients with disseminated neoplasia

Design

Cohort

Authors

RORobert M. OʼBryanHenry Ford Hospital JLJames K. LuceCleveland Clinic RTRobert W. TalleyLiberty University

Discussion

Member takes

Implication

Supports adriamycin evaluation in lymphomas, sarcomas, and breast cancer; leaves open safe dosing strategies given cardiotoxicity risk.

Structured PICO

Does adriamycin induce objective remissions and what is its toxicity profile in patients with disseminated neoplasia?

Population

472 patients with disseminated neoplasia

Intervention

Adriamycin (initial dose 75 mg/m2 every 3 weeks for good risk patients, 60 mg/m2 every 3 weeks for poor risk patients)

Outcome

Objective remissionshard clinical

Adriamycin is an active chemotherapeutic agent that produces prompt remissions, but it is associated with cumulative cardiotoxicity including irreversible congestive heart failure.

Cite This Study

OʼBryan et al. (1973) studied this question.

synapsesocial.com/papers/69f7e2ea6d1e8212df5a2c0d https://doi.org/10.1002/1097-0142(197307)32:1<1::aid-cncr2820320101>3.0.co;2-x

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Phase II evaluation of adriamycin in human neoplasia

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Phase II evaluation of adriamycin in human neoplasia

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider